AFP and neoplasm: Patients in the low-risk or A subgroup, characterized by tumor burdens within the up-to-11 criteria, a Child–Pugh score of 5–6, a unilobar tumor location, and serum AFP levels < 400 ng/mL, will likely derive the greatest benefit from TACE.